At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Tretinoindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
In Brief
A Phase 2 clinical trial evaluating Tretinoin for Adenoid Cystic Carcinoma. Completed, enrolled 18 participants across 2 sites.
Detailed Summary
This research is studying how safe and effective all-trans retinoic acid (ATRA), is to treat advanced adenoid cystic carcinoma (ACC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenoid Cystic Carcinoma
CountriesUnited States
CollaboratorsThe V Foundation, Adenoid Cystic Carcinoma Research Foundation
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartAug 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedJun 27, 2019
Enrollment StartAug 5, 2019
Primary CompletionApr 15, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.0 years ago
Interventions
Tretinoindrug
ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)